Expanding access to a breakthrough treatment option for patients with metastatic melanoma, Roswell Park Comprehensive Cancer Center has been approved to administer the newly FDA-approved tumor-infiltrating lymphocyte (TIL) therapy Amtagvi. This “living drug” cell therapy is manufactured by Iovance Biotherapeutics.

A preclinical study led by a team of researchers at Roswell Park Comprehensive Cancer Center highlights the potential of a novel two-drug treatment strategy targeting p53-mutant cancers. The findings, recently published in Cell Reports Medicine, lay the groundwork for further research, including a phase 1 clinical trial of colon cancer patients that is currently underway.

Researchers from the Health Behavior Department at Roswell Park Comprehensive Cancer Center have released a report showing the potential impacts of eliminating the sale of menthol cigarettes in the City of Buffalo. Their analysis was uncovered from data sources including the New York State Cancer Registry, the United State Census Bureau and other recent research on the impact of menthol cigarette bans.

The Chief of Myeloma at Roswell Park Comprehensive Cancer Center will deliver the latest findings of the CARTITUDE-2 clinical trial at the 2024 Tandem Transplantation & Cellular Therapy Meetings of the American Society for Transplantation and Cellular Therapy (ASTCT) and Center for International Blood and Marrow Transplant Research (CIBMTR), running Feb. 21-24 in San Antonio, Texas.